LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,113
تعداد مقالات10,208
تعداد مشاهده مقاله40,771,307
تعداد دریافت فایل اصل مقاله8,800,433
Taheri-Anganeh, Mortaza, Savardashtaki, Amir, Vafadar, Asma, Movahedpour, Ahmad, Shabaninejad, Zahra, Maleksabet, Amir, Amiri, Ahmad, Ghasemi, Younes, Irajie, Cambyz. (1399). In Silico Design and Evaluation of PRAME+FliCΔD2D3 as a New Breast Cancer Vaccine Candidate. سامانه مدیریت نشریات علمی, 46(1), 52-60. doi: 10.30476/ijms.2019.82301.1029
Mortaza Taheri-Anganeh; Amir Savardashtaki; Asma Vafadar; Ahmad Movahedpour; Zahra Shabaninejad; Amir Maleksabet; Ahmad Amiri; Younes Ghasemi; Cambyz Irajie. "In Silico Design and Evaluation of PRAME+FliCΔD2D3 as a New Breast Cancer Vaccine Candidate". سامانه مدیریت نشریات علمی, 46, 1, 1399, 52-60. doi: 10.30476/ijms.2019.82301.1029
Taheri-Anganeh, Mortaza, Savardashtaki, Amir, Vafadar, Asma, Movahedpour, Ahmad, Shabaninejad, Zahra, Maleksabet, Amir, Amiri, Ahmad, Ghasemi, Younes, Irajie, Cambyz. (1399). 'In Silico Design and Evaluation of PRAME+FliCΔD2D3 as a New Breast Cancer Vaccine Candidate', سامانه مدیریت نشریات علمی, 46(1), pp. 52-60. doi: 10.30476/ijms.2019.82301.1029
Taheri-Anganeh, Mortaza, Savardashtaki, Amir, Vafadar, Asma, Movahedpour, Ahmad, Shabaninejad, Zahra, Maleksabet, Amir, Amiri, Ahmad, Ghasemi, Younes, Irajie, Cambyz. In Silico Design and Evaluation of PRAME+FliCΔD2D3 as a New Breast Cancer Vaccine Candidate. سامانه مدیریت نشریات علمی, 1399; 46(1): 52-60. doi: 10.30476/ijms.2019.82301.1029

In Silico Design and Evaluation of PRAME+FliCΔD2D3 as a New Breast Cancer Vaccine Candidate

Iranian Journal of Medical Sciences
مقاله 6، دوره 46، شماره 1، فروردین 2021، صفحه 52-60    اصل مقاله (945.27 K)
نوع مقاله: Original Article(s)
شناسه دیجیتال (DOI): 10.30476/ijms.2019.82301.1029
نویسندگان
Mortaza Taheri-Anganeh1؛ Amir Savardashtaki1، 2؛ Asma Vafadar1؛ Ahmad Movahedpour1، 3؛ Zahra Shabaninejad2، 4؛ Amir Maleksabet5؛ Ahmad Amiri6؛ Younes Ghasemi1، 2، 7؛ Cambyz Irajie* 1
1Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran
2Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
3Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran
4Department of Nanobiotechnology, School of Biological Sciences, Tarbiat Modares University, Tehran, Iran
5Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Mazandaran University of Medical Sciences, Sari, Iran
6Department of Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
7Department of Pharmaceutical Biotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
چکیده
Background: The most prevalent cancer in women over the world is breast cancer. Immunotherapy is a promising method to effectively treat cancer patients. Among various immunotherapy methods, tumor antigens stimulate the immune system to eradicate cancer cells. Preferentially expressed antigen in melanoma (PRAME) is mainly overexpressed in breast cancer cells, and has no expression in normal tissues. FliCΔD2D3, as truncated flagellin (FliC), is an effective toll-like receptor 5 (TLR5) agonist with lower inflammatory responses. The objective of the present study was to utilize bioinformatics methods to design a chimeric protein against breast cancer.
Methods: The physicochemical properties, solubility, and secondary structures of PRAME+FliCΔD2D3 were predicted using the tools ProtParam, Protein-sol, and GOR IV, respectively. The 3D structure of the chimeric protein was built using I-TASSER and refined with GalaxyRefine, RAMPAGE, and PROCHECK. ANTIGENpro and VaxiJen were used to evaluate protein antigenicity, and allergenicity was checked using AlgPred and Allergen FP. Major histocompatibility complex
)MHC( and cytotoxic T-lymphocytes )CTL( binding peptides were predicted using HLApred and CTLpred. Finally, B-cell continuous and discontinuous epitopes were predicted using ABCpred and ElliPro, respectively.
Results: The stability and solubility of PRAME+FliCΔD2D3 were analyzed, and its secondary and tertiary structures were predicted. The results showed that the derived peptides could bind to MHCs and CTLs. The designed chimeric protein possessed both linear and conformational epitopes with a high binding affinity to B-cell epitopes.
Conclusion: PRAME+FliCΔD2D3 is a stable and soluble chimeric protein that can stimulate humoral and cellular immunity. The obtained results can be utilized for the development of an experimental vaccine against breast cancer.
کلیدواژه‌ها
PRAME antigen؛ Vaccines؛ Breast neoplasms؛ Computer simulation
سایر فایل های مرتبط با مقاله
مراجع
  1. Hamdan D, Nguyen TT, Leboeuf C, Meles S, Janin A, Bousquet G. Genomics applied to the treatment of breast cancer. Oncotarget. 2019;10:4786-801. doi: 10.18632/oncotarget.27102. PubMed PMID: 31413819; PubMed Central PMCID: PMCPMC6677666.
  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7-34. doi: 10.3322/caac.21551. PubMed PMID: 30620402
  3. World Health Organization. Global status report on noncommunicable diseases 2014. Geneva: World Health Organization; 2014.
  4. Ravi M, Sneka MK, Joshipura A. The culture conditions and outputs from breast cancer cell line in vitro experiments. Exp Cell Res. 2019;383:111548. doi: 10.1016/j.yexcr.2019.111548. PubMed PMID: 31398351.
  5. Lanari C, Wargon V, Rojas P, Molinolo AA. Antiprogestins in breast cancer treatment: are we ready? Endocr Relat Cancer. 2012;19:R35-50. doi: 10.1530/ERC-11-0378. PubMed PMID: 22351709.
  6. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087-106. doi: 10.1016/S0140-6736(05)67887-7. PubMed PMID: 16360786.
  7. Zhou J, Zhong Y. Breast cancer immunotherapy. Cell Mol Immunol. 2004;1:247-55. PubMed PMID: 16225767.
  8. Mohseni MM, Amani J, Gheybi E, Salmanian AH. In silico analysis of chimeric subunit vaccine containing HER-2-MUC1 against breast cancer. 2018;17:224-33.
  9. Parvizpour S, Razmara J, Pourseif MM, Omidi Y. In silico design of a triple-negative breast cancer vaccine by targeting cancer testis antigens. Bioimpacts. 2019;9:45-56. doi: 10.15171/bi.2019.06. PubMed PMID: 30788259; PubMed Central PMCID: PMCPMC6378095.
  10. Wadelin F, Fulton J, McEwan PA, Spriggs KA, Emsley J, Heery DM. Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia. Mol Cancer. 2010;9:226. doi: 10.1186/1476-4598-9-226. PubMed PMID: 20799951; PubMed Central PMCID: PMCPMC2936344.
  11. Epping MT, Wang L, Edel MJ, Carlee L, Hernandez M, Bernards R. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell. 2005;122:835-47. doi: 10.1016/j.cell.2005.07.003. PubMed PMID: 16179254.
  12. Ikeda H, Lethe B, Lehmann F, van Baren N, Baurain JF, de Smet C, et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity. 1997;6:199-208. doi: 10.1016/s1074-7613(00)80426-4. PubMed PMID: 9047241.
  13. Oberthuer A, Hero B, Spitz R, Berthold F, Fischer M. The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin Cancer Res. 2004;10:4307-13. doi: 10.1158/1078-0432.CCR-03-0813. PubMed PMID: 15240516.
  14. Zhang W, Barger CJ, Eng KH, Klinkebiel D, Link PA, Omilian A, et al. PRAME expression and promoter hypomethylation in epithelial ovarian cancer. Oncotarget. 2016;7:45352-69. doi: 10.18632/oncotarget.9977. PubMed PMID: 27322684; PubMed Central PMCID: PMCPMC5216727.
  15. Szczepanski MJ, Whiteside TL. Elevated PRAME expression: what does this mean for treatment of head and neck squamous cell carcinoma? Biomark Med. 2013;7:575-8. doi: 10.2217/bmm.13.68. PubMed PMID: 23905893; PubMed Central PMCID: PMCPMC3888223.
  16. Doolan P, Clynes M, Kennedy S, Mehta JP, Crown J, O’Driscoll L. Prevalence and prognostic and predictive relevance of PRAME in breast cancer. Breast Cancer Res Treat. 2008;109:359-65. doi: 10.1007/s10549-007-9643-3. PubMed PMID: 17624586.
  17. Song L, Xiong D, Song H, Wu L, Zhang M, Kang X, et al. Mucosal and Systemic Immune Responses to Influenza H7N9 Antigen HA1-2 Co-Delivered Intranasally with Flagellin or Polyethyleneimine in Mice and Chickens. Front Immunol. 2017;8:326. doi: 10.3389/fimmu.2017.00326. PubMed PMID: 28424686; PubMed Central PMCID: PMCPMC5380672.
  18. Dubensky TW, Jr., Reed SG. Adjuvants for cancer vaccines. Semin Immunol. 2010;22:155-61. doi: 10.1016/j.smim.2010.04.007. PubMed PMID: 20488726.
  19. Smith KD, Andersen-Nissen E, Hayashi F, Strobe K, Bergman MA, Barrett SL, et al. Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat Immunol. 2003;4:1247-53. doi: 10.1038/ni1011. PubMed PMID: 14625549.
  20. Yoshioka K, Aizawa S, Yamaguchi S. Flagellar filament structure and cell motility of Salmonella typhimurium mutants lacking part of the outer domain of flagellin. J Bacteriol. 1995;177:1090-3. doi: 10.1128/jb.177.4.1090-1093.1995. PubMed PMID: 7860589; PubMed Central PMCID: PMCPMC176707.
  21. Mizel SB, Bates JT. Flagellin as an adjuvant: cellular mechanisms and potential. J Immunol. 2010;185:5677-82. doi: 10.4049/jimmunol.1002156. PubMed PMID: 21048152; PubMed Central PMCID: PMCPMC3756556.
  22. Song L, Xiong D, Kang X, Jiao Y, Zhou X, Wu K, et al. The optimized fusion protein HA1-2-FliCDeltaD2D3 promotes mixed Th1/Th2 immune responses to influenza H7N9 with low induction of systemic proinflammatory cytokines in mice. Antiviral Res. 2019;161:10-9. doi: 10.1016/j.antiviral.2018.10.027. PubMed PMID: 30389471.
  23. Xiao Y, Liu F, Yang J, Zhong M, Zhang E, Li Y, et al. Over-activation of TLR5 signaling by high-dose flagellin induces liver injury in mice. Cell Mol Immunol. 2015;12:729-42. doi: 10.1038/cmi.2014.110. PubMed PMID: 25418468; PubMed Central PMCID: PMCPMC4716618.
  24. Karkhah A, Saadi M, Nouri HR. In silico analyses of heat shock protein 60 and calreticulin to designing a novel vaccine shifting immune response toward T helper 2 in atherosclerosis. Comput Biol Chem. 2017;67:244-54. doi: 10.1016/j.compbiolchem.2017.01.011. PubMed PMID: 28189968.
  25. Singh R. Bioinformatics: genomics and proteomics. Uttar Pradesh: Vikas Publishing House; 2015.
  26. Tabatabaei Mirakabad FS, Akbarzadeh A, Milani M, Zarghami N, Taheri-Anganeh M, Zeighamian V, et al. A Comparison between the cytotoxic effects of pure curcumin and curcumin-loaded PLGA-PEG nanoparticles on the MCF-7 human breast cancer cell line. Artif Cells Nanomed Biotechnol. 2016;44:423-30. doi: 10.3109/21691401.2014.955108. PubMed PMID: 25229832.
  27. Gitlin I, Carbeck JD, Whitesides GM. Why are proteins charged? Networks of charge-charge interactions in proteins measured by charge ladders and capillary electrophoresis. Angew Chem Int Ed Engl. 2006;45:3022-60. doi: 10.1002/anie.200502530. PubMed PMID: 16619322.
  28. Amala S. In silico analysis and 3D modeling of ASAH1 protein in farber lipogranulomatosis. Advanced Biotech. 2010;10:6-8.
  29. Kouza M, Faraggi E, Kolinski A, Kloczkowski A. The GOR Method of Protein Secondary Structure Prediction and Its Application as a Protein Aggregation Prediction Tool. Methods Mol Biol. 2017;1484:7-24. doi: 10.1007/978-1-4939-6406-2_2. PubMed PMID: 27787816.
  30. Abrusan G, Marsh JA. Alpha Helices Are More Robust to Mutations than Beta Strands. PLoS Comput Biol. 2016;12:e1005242. doi: 10.1371/journal.pcbi.1005242. PubMed PMID: 27935949; PubMed Central PMCID: PMCPMC5147804.
  31. Farjadian S, Naruse T, Kawata H, Ghaderi A, Bahram S, Inoko H. Molecular analysis of HLA allele frequencies and haplotypes in Baloch of Iran compared with related populations of Pakistan. Tissue Antigens. 2004;64:581-7. doi: 10.1111/j.1399-0039.2004.00302.x. PubMed PMID: 15496201.
  32. Gonzalez-Galarza FF, Takeshita LY, Santos EJ, Kempson F, Maia MH, da Silva AL, et al. Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations. Nucleic Acids Res. 2015;43:D784-8. doi: 10.1093/nar/gku1166. PubMed PMID: 25414323; PubMed Central PMCID: PMCPMC4383964.
  33. Awad Elkareem M, Ahmed Osman S, Mohamed H. Prediction and conservancy analysis of multiepitope based peptide vaccine against merkel cell polyomavirus: an immunoinformatics approach. Immun Res. 2017;13:2. doi: 10.4172/1745-7580.1000134.
  34. Potocnakova L, Bhide M, Pulzova LB. An Introduction to B-Cell Epitope Mapping and In Silico Epitope Prediction. J Immunol Res. 2016;2016:6760830. doi: 10.1155/2016/6760830. PubMed PMID: 28127568; PubMed Central PMCID: PMCPMC5227168.
آمار
تعداد مشاهده مقاله: 3,957
تعداد دریافت فایل اصل مقاله: 2,911


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب